Table 4. The most commonly used medications in total and in different polypharmacy status.
| Total | Non-polypharmacy | Cumulative polypharmacy | Consecutive polypharmacy | ||||
|---|---|---|---|---|---|---|---|
| Pharmacological subgroup (ATC-4) | Proportion (%) |
Pharmacological subgroup (ATC-4) | Proportion (%) |
Pharmacological subgroup (ATC-4) | Proportion (%) |
Pharmacological subgroup (ATC-4) | Proportion (%) |
| Glucocorticoids (H02AB) |
50.02 | Glucocorticoids (H02AB) |
18.26 | Glucocorticoids (H02AB) |
60.66 | HMG-CoA reductase inhibitors (C10AA) |
83.54 |
| HMG-CoA reductase inhibitors (C10AA) |
42.73 | Acetic acid derivatives and related substances (M01AB) |
11.06 | HMG-CoA reductase Inhibitors (C10AA) |
53.94 | Platelet aggregation inhibitors excl. heparin (B01AC) |
82.84 |
| Platelet aggregation inhibitors excl. heparin (B01AC) |
41.92 | Vitamin D and analogues (A11CC) |
9.97 | Platelet aggregation inhibitors excl. heparin (B01AC) |
52.90 | Glucocorticoids (H02AB) |
79.62 |
| Acetic acid derivatives and related substances (M01AB) |
36.83 | Fluoroquinolones (J01MA) |
9.75 | Angiotensin-II receptor blockers (ARBs), plain (C09CA) |
45.97 | Angiotensin-II receptor blockers (ARBs), plain (C09CA) |
76.22 |
| Angiotensin-II receptor blockers (ARBs), plain (C09CA) |
36.31 | Antibiotics, ophthalmological (S01AA) |
9.29 | Acetic acid derivatives and related substances (M01AB) |
45.46 | Anilides (N02BE) |
74.68 |
| Vitamin D And analogues (A11CC) |
35.80 | HMG-CoA reductase inhibitors (C10AA) |
9.29 | Anilides (N02BE) |
44.98 | H2-receptor antagonists (A02BA) |
72.53 |
| Anilides (N02BE) |
35.67 | Platelet aggregation inhibitors excl. heparin (B01AC) |
9.14 | Vitamin D and analogues (A11CC) |
44.45 | Acetic acid derivatives and related substances (M01AB) |
71.50 |
| H2-receptor antagonists (A02BA) |
32.78 | Corticosteroids, ophthalmological (S03BA) |
8.79 | H2-Receptor antagonists (A02BA) |
41.43 | Vitamin D And analogues (A11CC) |
70.49 |
| Third-generation cephalosporins (J01DD) |
32.10 | Third-generation cephalosporins (J01DD) |
7.96 | Third-generation cephalosporins (J01DD) |
40.18 | Third-generation cephalosporins (J01DD) |
67.61 |
| Beta blocking agents, selective (C07AB) |
30.17 | Anilides (N02BE) |
7.89 | Beta blocking agents, selective (C07AB) |
38.38 | Beta-blocking agents, selective (C07AB) |
65.31 |
| Fluoroquinolones (J01MA) |
27.48 | Angiotensin-II receptor blockers (ARBs), plain (C09CA) |
7.46 | Fluoroquinolones (J01MA) |
33.42 | Proton pump inhibitors (A02BC) |
62.57 |
| Proton pump inhibitors (A02BC) |
26.24 | H2-receptor antagonists (A02BA) |
6.95 | Proton pump inhibitors (A02BC) |
33.30 | Benzodiazepine derivatives (N05BA) |
61.34 |
| Benzodiazepine derivatives (N05BA) |
26.05 | Corticosteroids, plain, ophthalmological (S01BA) |
6.38 | Benzodiazepine derivatives (N05BA) |
33.07 | Organic nitrates (C01DA) |
61.19 |
| Macrolides (J01FA) |
25.15 | First-generation cephalosporins (J01DB) |
5.80 | Macrolides (J01FA) |
31.90 | Macrolides (J01FA) |
55.84 |
| Organic nitrates (C01DA) |
24.70 | Beta-blocking agents, selective (C07AB) |
5.66 | Organic nitrates (C01DA) |
31.85 | Fluoroquinolones (J01MA) |
55.43 |
ATC, Anatomical Therapeutic Chemical classification.